Sanofi SA
NASDAQ:SNY
Intrinsic Value
Sanofi engages in the research, production, and distribution of pharmaceutical products. [ Read More ]
The intrinsic value of one SNY stock under the Base Case scenario is 70.42 USD. Compared to the current market price of 49.25 USD, Sanofi SA is Undervalued by 30%.
Valuation Backtest
Sanofi SA
Run backtest to discover the historical profit from buying and selling SNY stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Sanofi SA
Current Assets | 30.7B |
Cash & Short-Term Investments | 8.7B |
Receivables | 391m |
Other Current Assets | 21.6B |
Non-Current Assets | 95.7B |
Long-Term Investments | 10.1B |
PP&E | 11.8B |
Intangibles | 73.6B |
Other Non-Current Assets | 203m |
Current Liabilities | 24B |
Accounts Payable | 20.9B |
Other Current Liabilities | 3.1B |
Non-Current Liabilities | 28.3B |
Long-Term Debt | 16.1B |
Other Non-Current Liabilities | 12.2B |
Earnings Waterfall
Sanofi SA
Revenue
|
46.4B
EUR
|
Cost of Revenue
|
-14.2B
EUR
|
Gross Profit
|
32.2B
EUR
|
Operating Expenses
|
-21.8B
EUR
|
Operating Income
|
10.4B
EUR
|
Other Expenses
|
-5B
EUR
|
Net Income
|
5.4B
EUR
|
Free Cash Flow Analysis
Sanofi SA
SNY Profitability Score
Profitability Due Diligence
Sanofi SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Sanofi SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
SNY Solvency Score
Solvency Due Diligence
Sanofi SA's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Sanofi SA's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SNY Price Targets Summary
Sanofi SA
According to Wall Street analysts, the average 1-year price target for SNY is 56.18 USD with a low forecast of 30.22 USD and a high forecast of 70.13 USD.
Shareholder Return
SAN Price
Sanofi SA
Average Annual Return | 10.66% |
Standard Deviation of Annual Returns | 15.75% |
Max Drawdown | -22% |
Market Capitalization | 114.9B EUR |
Shares Outstanding | 1 248 230 016 |
Percentage of Shares Shorted |
N/A
|
SNY News
Last Important Events
Sanofi SA
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Sanofi SA
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 95,442 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one SNY stock under the Base Case scenario is 70.42 USD.
Compared to the current market price of 49.25 USD, Sanofi SA is Undervalued by 30%.